Éric Jourdan

5.1k total citations
54 papers, 2.1k citations indexed

About

Éric Jourdan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Éric Jourdan has authored 54 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 18 papers in Genetics and 17 papers in Molecular Biology. Recurrent topics in Éric Jourdan's work include Acute Myeloid Leukemia Research (21 papers), Multiple Myeloma Research and Treatments (17 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Éric Jourdan is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Multiple Myeloma Research and Treatments (17 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Éric Jourdan collaborates with scholars based in France, Germany and United States. Éric Jourdan's co-authors include Bernard Klein, Jérôme Moreaux, Éric Legouffe, Thierry Rème, Karin Tarte, John De Vos, Jean‐François Rossi, Philippe Quittet, Philippe Le Moine and Michel Jourdan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncogene.

In The Last Decade

Éric Jourdan

52 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Jourdan France 18 1.3k 733 570 568 407 54 2.1k
Dario Ferrero Italy 25 1.0k 0.8× 872 1.2× 472 0.8× 338 0.6× 488 1.2× 92 2.0k
Carolina Terragna Italy 25 1.8k 1.4× 1.2k 1.7× 885 1.6× 311 0.5× 354 0.9× 99 2.3k
Toshiko Motoji Japan 26 1.5k 1.2× 915 1.2× 578 1.0× 399 0.7× 700 1.7× 121 2.6k
Shinichi Mizuno Japan 16 698 0.5× 1.0k 1.4× 405 0.7× 316 0.6× 210 0.5× 46 1.8k
Danielle Sainty France 25 1.7k 1.3× 1.2k 1.6× 623 1.1× 1.2k 2.1× 578 1.4× 74 3.0k
Todd M. Zimmerman United States 28 1.6k 1.2× 1.2k 1.7× 990 1.7× 313 0.6× 219 0.5× 95 2.2k
Christine Arnoulet France 28 1.6k 1.2× 885 1.2× 624 1.1× 809 1.4× 702 1.7× 69 2.6k
Edgar Jost Germany 23 551 0.4× 1.0k 1.4× 392 0.7× 314 0.6× 318 0.8× 100 1.8k
Masayuki Towatari Japan 27 1.6k 1.2× 1.7k 2.3× 570 1.0× 433 0.8× 595 1.5× 40 2.9k
Hélène A. Poirel Belgium 23 778 0.6× 804 1.1× 674 1.2× 351 0.6× 637 1.6× 56 2.1k

Countries citing papers authored by Éric Jourdan

Since Specialization
Citations

This map shows the geographic impact of Éric Jourdan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Jourdan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Jourdan more than expected).

Fields of papers citing papers by Éric Jourdan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Jourdan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Jourdan. The network helps show where Éric Jourdan may publish in the future.

Co-authorship network of co-authors of Éric Jourdan

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Jourdan. A scholar is included among the top collaborators of Éric Jourdan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Jourdan. Éric Jourdan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quittet, Philippe, et al.. (2022). Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania. Annals of Hematology. 101(5). 1015–1022. 1 indexed citations
2.
Willekens, Christophe, Odile Blanchet, Aline Renneville, et al.. (2015). Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica. 101(3). 328–335. 87 indexed citations
3.
Micol, Jean‐Baptiste, Nicolas Duployez, Nicolas Boissel, et al.. (2014). Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 124(9). 1445–1449. 69 indexed citations
4.
Ghobrial, Irene M., Philippe Moreau, Brianna Harris, et al.. (2012). A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia. Clinical Cancer Research. 18(18). 5043–5050. 25 indexed citations
5.
Nerich, Virginie, Bruno Lioure, Christian Récher, et al.. (2011). Induction-related cost of patients with acute myeloid leukaemia in France. International Journal of Clinical Pharmacy. 33(2). 191–199. 17 indexed citations
6.
Pigneux, Arnaud, Jean‐Luc Harousseau, Francis Witz, et al.. (2010). Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS. Journal of Clinical Oncology. 28(18). 3028–3034. 26 indexed citations
7.
Henry, Laurent, Christophe Delfour, Anne Arnaud, et al.. (2008). Association of Familial Pernicious Anaemia and Hereditary Haemochromatosis. Acta Haematologica. 119(1). 12–14. 3 indexed citations
8.
Lioure, Bruno, Christian Récher, Patrice Chevallier, et al.. (2008). Absolute Lymphocyte Count at 1st Remission Is Prognostic Factor for Disease Free and Overall Survival for Acute Myeloid Leukemia Under 60: Analysis of AML1 GOELAMS Trial. Blood. 112(11). 2520–2520. 1 indexed citations
9.
Moreaux, Jérôme, Dirk Hose, Thierry Rème, et al.. (2006). CD200 is a new prognostic factor in multiple myeloma. Blood. 108(13). 4194–4197. 191 indexed citations
10.
Hose, Dirk, John De Vos, Nadine Müller, et al.. (2006). Clonal and Subclonal Cytogenetic Aberrations: Association with D-Type Cyclin Expression and Event-Free Survival (EFS) in Multiple Myeloma (MM).. Blood. 108(11). 3439–3439. 1 indexed citations
11.
Jourdan, Éric, Françoise Rigal‐Huguet, Gérald Marit, et al.. (2005). Oneversustwo high‐dose cytarabine‐based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology. 129(3). 403–410. 11 indexed citations
12.
13.
Jourdan, Éric, Jean‐Michel Boiron, Nicole Dastugue, et al.. (2005). Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. Journal of Clinical Oncology. 23(30). 7676–7684. 39 indexed citations
14.
Mahtouk, Karène, Dirk Hose, Thierry Rème, et al.. (2005). Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. 24(21). 3512–3524. 80 indexed citations
15.
Moreaux, Jérôme, Friedrich W. Cremer, Thierry Rème, et al.. (2005). The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 106(3). 1021–1030. 197 indexed citations
16.
Jourdan, Éric, et al.. (2004). Zinc‐metallothionein genoprotective effect is independent of the glutathione depletion in HaCaT keratinocytes after solar light irradiation. Journal of Cellular Biochemistry. 92(3). 631–640. 16 indexed citations
17.
18.
Moreaux, Jérôme, Éric Legouffe, Éric Jourdan, et al.. (2003). BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 103(8). 3148–3157. 429 indexed citations
19.
Klein, Bernard, Karin Tarte, Michel Jourdan, et al.. (2003). Survival and Proliferation Factors of Normal and Malignant Plasma Cells. International Journal of Hematology. 78(2). 106–113. 175 indexed citations
20.
Boulat, Olivier, Françoise Rigal‐Huguet, Lysiane Molina, et al.. (2001). A Randomized Prospective Multicentre Trial of Cefpirome Versus Piperacillin-Tazobactam in Febrile Neutropenia. Leukemia & lymphoma. 42(3). 379–386. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dario Ferrero Breakdown of academic impact, for papers by Carolina Terragna Breakdown of academic impact, for papers by Toshiko Motoji Breakdown of academic impact, for papers by Shinichi Mizuno Breakdown of academic impact, for papers by Danielle Sainty Breakdown of academic impact, for papers by Todd M. Zimmerman Breakdown of academic impact, for papers by Christine Arnoulet Breakdown of academic impact, for papers by Edgar Jost Breakdown of academic impact, for papers by Masayuki Towatari Breakdown of academic impact, for papers by Hélène A. Poirel
Rankless by CCL
2026